Table 3.
Clinicopathologic characteristics of the SLE patients from validation cohort.
| Validation cohort | SLE_A (n = 20) | SLE_I (n = 20) |
|---|---|---|
| Age, (mean ± SD) | 33 ± 10 | 33 ± 11 |
| Sex, Female (%) | 19 (95) | 19 (95) |
| Clinical Criteria | ||
| Rash (%) | 3 (15) | 2 (20) |
| Oral ulcers (%) | 0 | 0 |
| Nonscarring alopecia (%) | 0 | 1 (5) |
| Fever (%) | 4 (20) | 3 (15) |
| Serositis (%) | 2 (10) | 1 (5) |
| Renal disorder (%) | 12 (60) | 1 (5) |
| Neurologic disorder (%) | 0 | 0 |
| Leukopenia (< 3000/mm3, (%)) | 6 (30) | 1 (5) |
| Thrombocytopenia (<100,000/mm3, (%)) | 4 (20) | 0 |
| LAC, (mean ± SD) | 1.3 ± 0.5 | 1.1 ± 0.1 |
| APTT, (sec, mean ± SD) | 34.5 ± 10.4 | 31.5 ± 3.7 |
| PT, (sec, mean ± SD) | 11.7 ± 1.1 | 12.0 ± 1.7 |
| ESR, (mm/h, mean ± SD) | 39.2 ± 32.7 | 12.6 ± 9.3 |
| CRP, (mg/L, mean ± SD) | 8.3 ± 9.3 | 5.4 ± 10.4 |
| Immunological Criteria | ||
| Positive ANA (%) | 20 (100) | 15 (75) |
| Anti-dsDNA (%) | 13 (65) | 6 (30) |
| Anti-β2GPI, (AU/ml, mean (range)) | 6.6 (1.6-46.8) | 5.7 (1.6-23.3) |
| ACL-IgG, (GPLU/ml, mean (range)) | 6.2 (1.4-32.2) | 5.1 (1.0-18.6) |
| ACL-IgM, (MPLU/ml, mean (range)) | 4.0 (1.5-22.5) | 3.0 (2-7.4) |
| Low C3 (%) | 19 (95) | 8 (40) |
| Low C4 (%) | 17 (85) | 8 (40) |
| Current drug use | ||
| Prednison (%) | 9 (45) | 7 (35) |
| Methylprednisolone (%) | 10 (50) | 11 (55) |
| Hydroxychloroquine (%) | 16 (80) | 19 (95) |
| Ciclosporin (%) | 4 (20) | 1 (5) |
| Methotrexate (%) | 0 | 3 (15) |
| Mycophenolate mofetil (%) | 5 (25) | 3 (15) |
| Oral anticoagulant (%) | 0 | 0 |
| Aspirin (%) | 5 (25) | 1 (5) |
All included SLE patients were detected positive ANA at least one time to satisfy 2019 EULAR/ACR SLE classification criteria. While SLE blood samples collecting, ANA of some SLE patients may turn negative. SD, standard deviation; LAC, lupus anticoagulant; APTT, activated partial thromboplastin time; PT, prothrombin time; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ANA, anti-nuclear antibody; Anti-dsDNA, anti-double strand DNA; Anti-β2GPI, anti-β2 glycoprotein I; ACL-IgG, anticardiolipin antibody-IgG; ACL-IgM, anticardiolipin antibody-IgM; C3, complement 3; C4, complement 4.